AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20731625 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h graded infusion of intralipid (20%)/heparin
Number of subjects: 8
Study 20731625 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 8
Study 20732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-20 mg/day for 8 weeks)
Number of subjects: 24
Study 20732372 — intervention group
Group type: COMPARATOR
Intervention: Benzamide antipsychotics (amisulpride and sulpiride)
Number of subjects: 24
Study 20732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 24
Study 20732794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 0
Study 20732794 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 20732988 — intervention group
Group type: EXPERIMENTAL
Intervention: O-secretor phenotype
Number of subjects: 253
Study 20733093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 15
Study 20733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 375
Study 20733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 375
Study 20733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 375
Study 20733447 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 375
Study 20735725 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous carriers of FV Leiden polymorphism
Number of subjects: 377155
Study 20735725 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous carriers of prothrombin polymorphism
Number of subjects: 377155
Study 20735725 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 377155
Study 20735725 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of FV Leiden polymorphism
Number of subjects: 377155
Study 20735725 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of prothrombin polymorphism
Number of subjects: 377155
Study 20739388 — intervention group
Group type: EXPERIMENTAL
Intervention: motesanib 125 mg once daily for up to 48 weeks
Number of subjects: 0
Study 20739421 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different diets (varying in protein and glycemic index content) after an 8-week low-calorie diet (800 kcal/d)
Number of subjects: 44
Study 20739421 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsuccessful group)
Number of subjects: 44
Study 20739682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine, allopurinol, or sulfamethoxazole
Number of subjects: 40
Study 20797845 — intervention group
Group type: EXPERIMENTAL
Intervention: L19-IL2 (22.5 Mio IU IL2 equivalent dose)
Number of subjects: 33
Study 20798939 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (80 mg/m2 as a 1-h infusion in a 21-day cycle for 3 cycles)
Number of subjects: 20
Study 20798939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (total dose of 45 mg, with 15 mg before docetaxel infusion and 30 mg before CYP3A assessment)
Number of subjects: 20
Study 20798939 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 mg oral)
Number of subjects: 20
Study 20801925 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of pmVSD
Number of subjects: 848
Study 20802024 — intervention group
Group type: EXPERIMENTAL
Intervention: Structurally complex karyotype (defined as ≥ 3 chromosomal aberrations including at least one structural aberration)
Number of subjects: 192
Study 20802024 — intervention group
Group type: EXPERIMENTAL
Intervention: Structurally complex karyotype without a monosomy
Number of subjects: 192
Study 20802024 — intervention group
Group type: COMPARATOR
Intervention: Normal karyotype
Number of subjects: 192
Study 20802164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Injury Prediction Score (LIPS)
Number of subjects: 5584
Study 20802164 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of ALI
Number of subjects: 5584
Study 20802164 — intervention group
Group type: EXPERIMENTAL
Intervention: ALI occurrence
Number of subjects: 5584
Study 20802164 — intervention group
Group type: EXPERIMENTAL
Intervention: ALI development
Number of subjects: 5584
Study 20802352 — intervention group
Group type: EXPERIMENTAL
Intervention: LungPoint navigation system
Number of subjects: 25
Study 20803190 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history
Number of subjects: 1144
Study 20803190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1144
Study 20803190 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) level, retinal and renal complications
Number of subjects: 1144
Study 20803190 — intervention group
Group type: COMPARATOR
Intervention: Macrovascular risk factors
Number of subjects: 1144
Study 20803390 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Buddy (HB) text messaging device
Number of subjects: 38
Study 20803390 — intervention group
Group type: COMPARATOR
Intervention: Telephone monitoring
Number of subjects: 38
Study 20803391 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Digital Fatigue Score (RDFS)
Number of subjects: 49
Study 20805112 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month for patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Number of subjects: 360
Study 20805112 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 20805112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 20807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 197
Study 20807873 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 197
Study 20807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CAC, Lp-PLA(2), and ACR
Number of subjects: 197
Study 20807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline calcium categories
Number of subjects: 197
Study 20807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-to-creatinine ratio (ACR)
Number of subjects: 197
Study 20807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2))
Number of subjects: 197
Study 20809967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 83
Study 20809967 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 70 μg/kg with glycopyrrolate 14 μg/kg
Number of subjects: 83
Study 20811065 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable capsular vitreous body (FCVB)
Number of subjects: 11
Study 20811392 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-21 ointment
Number of subjects: 8
Study 20811747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gallstones (n=103)
Number of subjects: 136
Study 20811747 — intervention group
Group type: COMPARATOR
Intervention: Patients without gallstones (n=33)
Number of subjects: 136
Study 20812783 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice redesign support with computerized provider feedback
Number of subjects: 295
Study 20812783 — intervention group
Group type: COMPARATOR
Intervention: Practice redesign support alone (comparison group)
Number of subjects: 295
Study 20812791 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (study drug)
Number of subjects: 596
Study 20812791 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous antipsychotic medication (used prior to enrollment)
Number of subjects: 596
Study 20812850 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, and 18), administered 0.5 mL intramuscularly at entry, week 8, and week 24.
Number of subjects: 109
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraventricular tachycardias
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-atrial re-entrant tachycardia (IART)
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CHQ physical summary score
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant rhythm
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of Fontan operation
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia
Number of subjects: 520
Study 20813285 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of IART
Number of subjects: 520
Study 20813797 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systemic lupus erythematosus (SLE)
Number of subjects: 50
Study 20813797 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 20813797 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLE (normotensive, without aortic plaques, non-smokers)
Number of subjects: 50
Study 20814049 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal Evolution (EVCD)
Number of subjects: 1004
Study 20814317 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150-300 mg/d)
Number of subjects: 40
Study 20814413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation (doubling baseline caloric intake with at least two fast food meals per day for 4 weeks)
Number of subjects: 18
Study 20814413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation
Number of subjects: 18
Study 20815188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute pulmonary embolism (PE)
Number of subjects: 270
Study 20815188 — intervention group
Group type: COMPARATOR
Intervention: Patients without pulmonary embolism (PE)
Number of subjects: 270
Study 20815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking antibodies (measured by HBGA blocking assay)
Number of subjects: 18
Study 20815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechallenge blocking titers (>25)
Number of subjects: 18
Study 20816019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell based cancer vaccine (MelCancerVac)
Number of subjects: 20
Study 20816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy
Number of subjects: 13
Study 20816040 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 20816873 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat-to-beat 3-dimensional vectorcardiogram variability (measured by T/R peaks cloud volume ratio)
Number of subjects: 414
Study 20816873 — intervention group
Group type: EXPERIMENTAL
Intervention: T peaks cloud volume
Number of subjects: 414
Study 20816873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular arrhythmia (VA) with appropriate ICD therapies
Number of subjects: 414
Study 20817711 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) diagnosis based on AHI >15 events·h⁻¹
Number of subjects: 641
Study 20817711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension as a risk factor for OSA in females
Number of subjects: 641
Study 20817711 — intervention group
Group type: COMPARATOR
Intervention: Comparison of females with and without OSA
Number of subjects: 641
Study 20818327 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches targeting androgen signaling
Number of subjects: 0
Study 20818327 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting Hedgehog signaling
Number of subjects: 0
Study 20818327 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting Src family kinases
Number of subjects: 0
Study 20818327 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting fibroblast growth factors and transforming growth factor beta signaling
Number of subjects: 0
Study 20818327 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting integrins
Number of subjects: 0
Study 20818854 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation
Number of subjects: 7
Study 20819219 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided oblique lumbar interbody fusion (GO-LIF) procedure
Number of subjects: 40
Study 20819467 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 101
Study 20819467 — intervention group
Group type: COMPARATOR
Intervention: Histological examination (mucosal eosinophilia and basement membrane thickening)
Number of subjects: 101
Study 20819968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (4 x 4 minutes at 90% of maximal heart rate, 40 minutes total, twice per week for 13 weeks)
Number of subjects: 10
Study 20819968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 10
Study 20819968 — intervention group
Group type: COMPARATOR
Intervention: Lean counterparts (control group)
Number of subjects: 10
Study 20821042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss intervention (Active Mothers Postpartum [AMP])
Number of subjects: 450
Study 20822542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg + methotrexate (MTX)
Number of subjects: 122
Study 20822542 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 122
Study 20822542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg + MTX
Number of subjects: 122
Study 20823398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 20823423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-doxorubicin-dexamethasone (BDD) therapy
Number of subjects: 68
Study 20823436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 + 1 doses of PCV-7 at 2, 4, and 11 months
Number of subjects: 948
Study 20823436 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 948
Study 20825369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' satisfaction with care assessed by a questionnaire upon discharge from ICU.
Number of subjects: 235
Study 20825369 — intervention group
Group type: COMPARATOR
Intervention: Next of kin's ratings of patients' satisfaction with care.
Number of subjects: 235
Study 20825640 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed interventional cardiologists
Number of subjects: 300
Study 20825640 — intervention group
Group type: COMPARATOR
Intervention: Non-interventional cardiologists (unexposed reference group)
Number of subjects: 300
Study 20825796 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based educational intervention and a home nursing education visit
Number of subjects: 105
Study 20825796 — intervention group
Group type: COMPARATOR
Intervention: Neither (control group)
Number of subjects: 105
Study 20825796 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 105
Study 20826251 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 1217
Study 20826251 — intervention group
Group type: COMPARATOR
Intervention: Control (no early revascularization)
Number of subjects: 1217
Study 20827267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 20830543 — intervention group
Group type: EXPERIMENTAL
Intervention: Central landmark technique in pregnant women
Number of subjects: 161
Study 20830543 — intervention group
Group type: COMPARATOR
Intervention: Central landmark technique in non-pregnant women
Number of subjects: 161
Study 20830543 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory approach in pregnant women
Number of subjects: 161
Study 20830543 — intervention group
Group type: COMPARATOR
Intervention: Palpatory approach in non-pregnant women
Number of subjects: 161
Study 20830543 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory technique in pregnant women
Number of subjects: 161
Study 20830543 — intervention group
Group type: COMPARATOR
Intervention: Palpatory technique in non-pregnant women
Number of subjects: 161
Study 20831796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50-300 mg/day)
Number of subjects: 66
Study 20831836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo® WiiFit
Number of subjects: 21
Study 20831836 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 21
Study 20832596 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 1
Study 20833684 — intervention group
Group type: COMPARATOR
Intervention: Control strategy (direct mail to men)
Number of subjects: 600
Study 20833684 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse strategy (indirect mail via wives)
Number of subjects: 600
Study 20833772 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy-confirmed myocarditis
Number of subjects: 119
Study 20833772 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable myocarditis
Number of subjects: 119
Study 20833772 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic dilated cardiomyopathy
Number of subjects: 119
Study 20833772 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with myocarditis with impaired LV ejection at presentation
Number of subjects: 119
Study 20833868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT) testing in subjects with type 1 diabetes
Number of subjects: 1177
Study 20833868 — intervention group
Group type: EXPERIMENTAL
Intervention: VPT cut points for defining abnormality
Number of subjects: 1177
Study 20833868 — intervention group
Group type: EXPERIMENTAL
Intervention: VPT testing
Number of subjects: 1177
Study 20837663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Number of subjects: 0
Study 20837778 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 24
Study 20837825 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 15
Study 20837881 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sinus fat (RS fat)
Number of subjects: 205
Study 20837883 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (0.5 mg BID)
Number of subjects: 14
Study 20837883 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (1.0 mg BID)
Number of subjects: 14
Study 20837883 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (4 weeks treatment)
Number of subjects: 14
Study 20837897 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor
Number of subjects: 297
Study 20837897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-degree atrioventricular block
Number of subjects: 297
Study 20837916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 1620
Study 20837927 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygote minor allele of rs10116277
Number of subjects: 846
Study 20837927 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of rs10116277 to the logistic EuroSCORE
Number of subjects: 846
Study 20837940 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25-mg weekly (Group A)
Number of subjects: 89
Study 20837940 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25-mg weekly (Group B)
Number of subjects: 89
Study 20837940 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25-mg weekly (Group C)
Number of subjects: 89
Study 20838360 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 × 200 macular cube scans
Number of subjects: 17
Study 20838360 — intervention group
Group type: EXPERIMENTAL
Intervention: 512 × 128 macular cube scans
Number of subjects: 17
Study 20838360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scanning protocols
Number of subjects: 17
Study 20838998 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg orally once daily for 48 weeks
Number of subjects: 102
Study 20838998 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib (18)FDG-PET
Number of subjects: 102
Study 20838998 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib Choi criteria
Number of subjects: 102
Study 20838998 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib
Number of subjects: 102
Study 20840760 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free combination therapy (basiliximab, MMF, steroids and delayed Sirolimus)
Number of subjects: 29
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Behavior Assessment (EBA)
Number of subjects: 0
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Platypus Appetite Rating Scale (PARS)
Number of subjects: 0
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Inventory (EI)
Number of subjects: 0
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Craving Inventory (FCI)
Number of subjects: 0
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Attitude Scale (EAS)
Number of subjects: 0
Study 20840778 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight changes (2-4 weeks)
Number of subjects: 0
Study 20840778 — intervention group
Group type: COMPARATOR
Intervention: Early appetite change
Number of subjects: 0
Study 20841416 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50 μg/kg/min)
Number of subjects: 16
Study 20841509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab plus alemtuzumab (10 mg of alemtuzumab subcutaneously on days 1 to 3, plus 100 mg of rituximab intravenously weekly in 4 doses)
Number of subjects: 21
Study 20843246 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB018424 (15 mg twice daily, individualized dose titration)
Number of subjects: 153
Study 20843246 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB018424
Number of subjects: 153
Study 20843247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 COPD
Number of subjects: 2138
Study 20843247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 COPD
Number of subjects: 2138
Study 20843247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 4 COPD
Number of subjects: 2138
Study 20843592 — intervention group
Group type: EXPERIMENTAL
Intervention: Thujone-free wormwood preparation (1.8 g/d for 6 months)
Number of subjects: 10
Study 20844233 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg orally per day for 3 weeks
Number of subjects: 12